# Inbiomotion SL

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/inbiomotion-sl

- Industry: Biotechnology
- Headquarters: Barcelona, Spain
- Website: www.inbiomotion.com
- Total disclosed funding: $2.5M
- Latest round: Series A (Jul 2, 2012)
- Investors on record: 1

## About

Inbiomotion SL is focused on advancing precision medicine through the MAF Test®, a specialized biomarker test that aids in optimizing treatment for early breast cancer patients, enhancing patient selection and management.Inbiomotion SL develops innovative solutions in precision medicine, particularly the MAF Test®, which aids in the treatment of early breast cancer. The company is headquartered in Barcelona, Spain. Founded by Anna Comas, Anna Farriol, and Roger Gomis, Inbiomotion has pivoted to focus on the commercialization of its biomarker test. In January 2021, the company raised EUR 2.20 mn in funding led by Caixa Capital Risc, with other investors including Fundacio Vila Casas and Ysios Capital Partners. This funding represents the total amount raised to date, enabling the company to expand its market reach.Inbiomotion specializes in precision medicine solutions, focusing on the MAF Test®, a biomarker test designed for early breast cancer patients. This test identifies patients likely to benefit from adjuvant bisphosphonate treatment while excluding those with unfavorable gene expression. Based on research from pivotal trials, Inbiomotion is expanding the availability of the MAF Test®, beginning with an exclusive distribution agreement in Italy, targeting oncologists and healthcare providers for personalized treatment.Inbiomotion reported a revenue of EUR 74,609.50 in 2023, with an EBITDA of EUR -492,524.90 for the same year. The company's revenue structure is derived from the distribution of the MAF Test® through strategic partnerships with healthcare institutions, focusing on enhancing patient management protocols in oncology.Inbiomotion plans to leverage recent funding to further develop the MAF Test® and expand into additional international markets. With the January 2021 funding, the company aims to enhance its product offerings and increase distribution efforts, particularly in regions beyond Italy. The growth strategy will focus on forming new partnerships with healthcare providers to improve personalized treatment protocols for breast cancer patients.

## Funding rounds

- Series A, Jul 2, 2012, $2.5M — Ysios Capital Partners

## Investors

- Ysios Capital Partners (https://capitalatlas.ai/funds/ysios-capital-partners) — Series A